ArticleCancer discovery2020
Type I Interferon Regulates a Coordinated Gene Network to Enhance Cytotoxic T Cell-Mediated Tumor Killing.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 66 citations in OpenAlex.
- Ursodeoxycholic acid enhances cancer radioimmunotherapy by releasing a human-biased FXR-TRIM22-STAT1 immune brake.Cell research · 2026Article
- Restoring STING expression in soft tissue sarcoma increases activation and function of tumor-infiltrating lymphocytes.Cancer immunology, immunotherapy : CII · 2026Article
- Antitumor effects of STING agonists on nervous system tumors via tumor-intrinsic STING-STAT1-mediated HMGN2 expression.Cancer biology & medicine · 2026Article
- Non-Coding RNAs as key regulators of interferon signaling in cancer immunotherapy: mechanistic insights and clinical prospects.Clinical and experimental medicine · 2026Review
- Unraveling the Biology of Interferon-Stimulated Genes: Mechanisms, Functions, and Clinical Implications.Infection and drug resistance · 2026Review
- Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Frontiers in immunology · 2026Review
- High-Throughput Synthesis and Screening of a Cyanimide Library Identifies Selective Inhibitors of ISG15-Specific Protease mUSP18.Angewandte Chemie (International ed. in English) · 2025Article
- The ISGylation tapestry in cancer: weaving phenotypic plasticity through multidimensional regulatory looms.Cellular & molecular biology letters · 2025Review
- Intron retention regulates STAT2 function and predicts immunotherapy response in lung cancer.bioRxiv : the preprint server for biology · 2025Article
- Molecular choreography of E1 enzymes in ubiquitin-like protein cascades: New insights into dynamics and specificity.The Journal of biological chemistry · 2025Review
- Genome-Wide Screening Reveals the Oncolytic Mechanism of Newcastle Disease Virus in a Human Colonic Carcinoma Cell Line.Viruses · 2025Article
- Molecular insights into immune evasion and therapeutic paradigms in pancreatic cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025Article
- Targeting USP18 overcomes acquired resistance in hepatocellular carcinoma by regulating NCOA4 deISGylation and ferroptosis.Cell death & disease · 2025Article
- Comparative Analysis of HMC3 and C20 Microglial Cell Lines Reveals Differential Myeloid Characteristics and Responses to Immune Stimuli.Immunology · 2025Review
- Chemical tools to define and manipulate interferon-inducible Ubl protease USP18.Nature communications · 2025Article
- Interferon-stimulated gene subtypes as key indicators of immune landscape and survival outcomes in ovarian cancer.Discover oncology · 2024Article
- cGAS/STING signalling pathway in senescence and oncogenesis.Seminars in cancer biology · 2024Review
- The identification of effective tumor-suppressing neoantigens using a tumor-reactive TIL TCR-pMHC ternary complex.Experimental & molecular medicine · 2024Article
- Chemical tools to define and manipulate interferon-inducible Ubl protease USP18.bioRxiv : the preprint server for biology · 2024Article
- Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 4 countries.
Jun-Bao FanMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California. d7zhang@ucsd.edu jbfan@ucsd.edu.ORCID https://orcid.org/0000-0002-1709-3659
Sayuri MiyauchiMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Hui-Zhong XuThe Salk Institute for Biological Sciences, La Jolla, California.
Dan LiuMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Leo J Y KimDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Christoph BurkartMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Hua ChengMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Kei-Ichiro ArimotoMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Ming YanMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California.
Yu ZhouState Key Laboratory of Virology, College of Life Science, Wuhan University, Wuhan, Hubei, China.ORCID https://orcid.org/0000-0002-2102-9377
Balázs GyőrffyDepartment of Bioinformatics, Semmelweis University, Budapest, Hungary.
Klaus-Peter KnobelochInstitute of Neuropathology, University of Freiburg, Freiburg, Germany.ORCID https://orcid.org/0000-0003-1587-1944
Jeremy N RichDivision of Regenerative Medicine, Department of Medicine, University of California, San Diego, La Jolla, California.
Hu CangThe Salk Institute for Biological Sciences, La Jolla, California.
Xiang-Dong FuDepartment of Cellular and Molecular Medicine, Institute of Genomic Medicine, University of California, San Diego, La Jolla, California.ORCID https://orcid.org/0000-0001-5499-8732
Dong-Er ZhangMoores UCSD Cancer Center, University of California, San Diego, La Jolla, California. d7zhang@ucsd.edu jbfan@ucsd.edu.
University of California San Diego · USSalk Institute for Biological Studies · USSemmelweis University · HUUniversity of Freiburg · DEWuhan University · CN
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DIANE M SIMEONE · 1985 to 2026
$124.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4MISG15 and Protein ISGylation in CancerR01CA177305 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2013 to 2023
$3.7MUltra Sensitive Single Molecule Spectroscopy With Plasmonic AntennasDP2EB020400 · NIBIB · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI CANG, HU · 2014 to 2014
$2.9MUSP18 in Cancer DevelopmentR01CA232147 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHANG, DONG-ER · 2019 to 2023
$1.9MNCI NIH HHS P30 CA023100NCI NIH HHS R01 CA177305NCI NIH HHS R01 CA232147NIBIB NIH HHS DP2 EB020400NIGMS NIH HHS T32 GM007250
Abstract
Type I interferons (IFN), which activate many IFN-stimulated genes (ISG), are known to regulate tumorigenesis. However, little is known regarding how various ISGs coordinate with one another in developing antitumor effects. Here, we report that the ISG
Indexed as
AnimalsBreast NeoplasmsCell ProliferationFemaleGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansInterferon Type IMiceSTAT1 Transcription FactorSTAT2 Transcription FactorT-LymphocytesTranscription FactorsUbiquitin-Activating EnzymesUbiquitinsInterferon Type ISTAT1 protein, humanSTAT1 Transcription FactorSTAT2 protein, humanSTAT2 Transcription FactorTranscription FactorsUBA7 protein, humanUbiquitin-Activating EnzymesUbiquitins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.